secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001159036-23-000020
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme says EPO revokes Janssen co-formulation patent; reaffirms 2023 guidance
--------------------------------------------------------------------------------

- EPO Opposition Division revoked Janssen's European Patent EP3370770B1 for DARZALEX SC co-formulation.
- Halozyme reiterates 2023 revenue guidance of $815M-$845M and royalty revenue of $445M-$455M.
- Affirms total royalty revenue projection of ~$1B by 2027 and thereafter to at least 2030.
- License with Janssen: co-formulation patents do not extend royalty step-down beyond 2024 in EU, 2027 in US.
- Written decision expected in months; if appeal filed, patent remains in force until final decision.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903623000020/0001159036-23-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903623000020/halo-20230315.htm
  HTML page:      https://secwatch.observer/filing/0001159036-23-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer